A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

BACKGROUND: KM-819 is a novel FAS-associated factor 1 (FAF1) inhibitor, and a neuroprotective agent, under clinical development for the treatment of Parkinson’s disease as a disease-modifying drug. METHODS: This first-in-human, single and multiple ascending dose study investigated the safety, tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Wonsuk, Lim, Kyoung Soo, Kim, Min-Kyoung, Kim, Hyun Sook, Hong, Jihwa, Jhee, Stanford, Kim, Joseph, Yoo, Sungeun, Chung, Yeon-Tae, Lee, Jae Moon, Cho, Doo-Yeoun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445238/
https://www.ncbi.nlm.nih.gov/pubmed/30992659
http://dx.doi.org/10.2147/DDDT.S198753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445238/
https://www.ncbi.nlm.nih.gov/pubmed/30992659
http://dx.doi.org/10.2147/DDDT.S198753

Ejemplares similares